Danish CNS specialist Lundbeck (LUND: CO) has reported record annual revenue for 2023 of 19.91 billion Danish kroner ($2.87 billion), a 9% increase on 2022.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) increased to 5.65 billion kroner, a rise of 17%, and adjusted EBITDA margin reached 28.4%, equivalent to an increase of 2%.
"We are currently in the process of strengthening Lundbeck’s position as a focused innovator to ensure a sustainable long-term future"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze